Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/IIa study of PLX-PAD cell therapy for the treatment of mild to moderate knee osteoarthritis (OA)

Next Previous
X
Search
Trial Profile

A phase I/IIa study of PLX-PAD cell therapy for the treatment of mild to moderate knee osteoarthritis (OA)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emiplacel (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 09 Sep 2022 New trial record
    • 06 Sep 2022 According to a Pluristem Therapeutics media release, this trial will be carried out by Charite, Pluri and other members of the international consortium under the leadership of Professor Tobias Winkler, Principal Investigator (PI) at the Berlin Institute of Health Center for Regenerative Therapies, Julius Wolff Institute and Center for Musculoskeletal Surgery.
    • 06 Sep 2022 According to a Pluristem Therapeutics media release, company announced that a 7.5 million euro non dilutive grant from the European Union Horizon Europe program has been awarded to PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis). The goal of the PROTO project is to utilize PLX-PAD cells in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top